Article

Drug-susceptibility patterns of Mycobacterium tuberculosis in Mpumalanga province, South Africa: possible guiding design of retreatment regimen.

AIDS Virus Research Laboratory, Department of Microbiology, University of Venda, South Africa.
Journal of Health Population and Nutrition (Impact Factor: 1.12). 02/2010; 28(1):7-13. DOI:10.3329/jhpn.v28i1.4518
Source: PubMed

ABSTRACT Multidrug-resistant tuberculosis (MDR-TB) has been a cause of concern in both developed and developing countries. The prevalence of drug resistance in Mycobacterium tuberculosis (MTB) isolates (n=692) from Mpumalanga province was assessed. In total, 692 (64%) MTB strains from cases with pulmonary TB were tested for susceptibility against rifampicin, isoniazid, ethambutol, and streptomycin using the MGIT 960 instrument. Two hundred and nine (30.2%) strains were resistant to one or more drugs. Resistance to one drug ranged from 1.4% for ethambutol to 17.7% for rifampicin. The prevalence of MDR-TB ranged from 6.7% for three drugs to 34% for four drugs, with significant predictors being patients' age-groups of 25-54 years (p=0.0012) and >55 years (p=0.007). The result showed a high level (58.4%) of MDR-TB from cases in Mpumalanga province. To achieve a higher cure rate in this province, drug-susceptibility tests must be done for every case.

0 0
 · 
0 Bookmarks
 · 
63 Views
  • Source
    [show abstract] [hide abstract]
    ABSTRACT: Anti-tubercolosi resistenza ai farmaci nel sud-est della Turchia]
  • [show abstract] [hide abstract]
    ABSTRACT: Drug resistance is a major obstacle to effective TB control program performance. In this study, we assessed the prevalence of primary drug resistance in Mycobacterium tuberculosis (Mtb) isolates in Amhara Region, Ethiopia. A total of 112 Mtb isolates from cases with newly diagnosed pulmonary TB were subjected to drug susceptibility testing (DST) in a cross-sectional study. Isolates were tested for sensitivity to isoniazid, rifampicin, ethambutol, and streptomycin using the MGIT 960 protocol. A total of 93 Mtb isolates yielded valid DST results and 28 (30.1%) were resistant to one or more of first line anti-TB drugs. One isolate (1.0%) was multi-drug resistant (MDR), five (5.4%) were classified as poly-resistant and 22 showed single drug resistance to either streptomycin (n = 19) or isoniazid (n = 3). Isolates from HIV-positive patients were more likely to be resistant to at least one of the four anti-TB drugs compared with HIV-negative individuals (odds ratio 2.76, 95% confidence interval 1.06-7.22; p = 0.03). The study showed a high prevalence of primary drug resistance. Even though the prevalence of MDR was low, conditions that can contribute to the development of MDR are increasing. Therefore, regular monitoring of drug resistance and enhanced implementation of TB/HIV collaborative activities in the study region are imperative.
    Apmis 06/2012; 120(6):503-9. · 2.07 Impact Factor
  • Source
    [show abstract] [hide abstract]
    ABSTRACT: ABSTRACT Emergence of multidrug-resistant tuberculosis (MDR-TB) has been a cause of concern in both developed and developing countries. Hence, there is a need for continuous monitoring of drug resistance to anti-tuberculosis drugs in tuberculosis patients. A study was conducted to determine the prevalence anti-TB drug resistance in Mycobacterium tuberculosis isolates obtained from sputum samples of clinically suspected TB patients with no history of previous anti-TB treatment attending a tertiary care hospital from February 2006 to August 2007 in Pune, India. Mycobacterium tuberculosis isolates were subjected to drug susceptibility testing (DST) to four firstline anti-TB drugs namely Isoniazid, Rifampicin, Streptomycin and Ethambutol by Bactec MGIT 960 system being currently used in the Revised National Tuberculosis Control Program (RNTCP). It was found that MDR-TB prevalence in newly diagnosed pulmonary tuberculosis patients in Pune has not increased compared to the earlier data. Adequate data on MDR-TB at national and regional level are not available. Hence, it is essential to conduct nationwide drug resistance surveillance for TB with continuous monitoring of trends to curb the emergence of drug resistance to ensure the success of tuberculosis control programs in the country.
    Int J Pharm Bio Sci. 07/2013; 4(3):579 - 585.

Full-text (2 Sources)

View
24 Downloads
Available from
Sep 20, 2012